IRCT20190928044912N1已完成2 期
Evaluation of treatment of actinic keratosis with 35% hydrogen peroxide in comparison to cryotherapy
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients who are at least 18 years old with at least 4 actinic keratosis on the skin areas that are sun exposed
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% CreamActintic keratosisMedDRA version: 20.0Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2020-003316-27-ATMedical University of Graz50
进行中（未招募）
不适用
Treatment of actinic keratoses with Birken-Oleogel in comparison to cryotherapy and the combination of cryotherapy plus Birken-Oleogel: a randomized, monocenter study.Behandlung aktinischer Keratosen mit Birken-Oleogel im Vergleich zu Kryotherapie und der Kombination Kryotherapie plus Birken-Oleogel: eine randomisierte, monozentrische StudieActinic keratoses. These are dysplasia of the epidermis caused by chronic UV-irradiation, that developwithout treatment in 20% of the cases into skin cancer (spinalioma).aktinische Keratosen. Dies sind durch chronische UV-Strahlung entstandene Dysplasien der Oberhaut (Epidermis), die bei fehlender Behandlung in ca 20% der Fälle in Hautkrebs (Plattenepithel-Carcinom) übergehen können.EUCTR2004-003917-17-DEBirken GmbH
进行中（未招募）
不适用
Treatment of Actinic Keratoses with Ingenol Mebutate and topical glucocorticosteroid - a safety studyActinic KeratosesMedDRA version: 14.1Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2013-002583-80-DKDepartment of Dermatology, Bispebjerg University Hospital21
尚未招募
不适用
Outcomes of corneal neurotizatioCTRI/2021/10/037280I
进行中（未招募）
不适用
Quality of life of patients with actinic keratoses and/or a superficial basal cell carcinoma treated with Imiquimod 5% cream.EUCTR2008-002501-39-NLMedaPharma500